NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.
Institute of Medicine (US) Committee on Cancer Clinical Trials and the NCI Cooperative Group Program; Nass SJ, Moses HL, Mendelsohn J, editors. A National Cancer Clinical Trials System for the 21st Century: Reinvigorating the NCI Cooperative Group Program. Washington (DC): National Academies Press (US); 2010.
A National Cancer Clinical Trials System for the 21st Century: Reinvigorating the NCI Cooperative Group Program.
Show details- AACI
Association of American Cancer Institutes
- AAMC
American Association of Medical Colleges
- ACOSOG
American College of Surgeons Oncology Group
- ACRIN
American College of Radiology Imaging Network
- ACS CAN
American Cancer Society Cancer Action Network
- AE
adverse event
- AHRQ
Agency for Healthcare Research and Quality
- AIPC
androgen-independent prostate cancer
- ALERT
Act 21st Century Cancer Access to Life-Saving Early Detection, Research, and Treatment Act
- ALL
acute lymphoblastic leukemia
- AML
acute myeloid leukemia
- ARRA
American Recovery and Reinvestment Act of 2009
- ASCO
American Society of Clinical Oncology
- BCG
bacillus Calmette-Guérin
- BICR
blinded independent central review
- BIG
Breast International Group
- BRB
Biometric Research Branch
- BSA
Board of Scientific Advisors (National Cancer Institute)
- CALGB
Cancer and Leukemia Group B
- CCG
Children’s Cancer Group
- CCOP
Community Clinical Oncology Program
- CCSG
Cancer Center Support Grant
- CER
comparative effectiveness research
- CHOP
cyclophosphamide, doxorubicin, vincristine, and prednisone
- CIRB
central institutional review board
- CLL
chronic lymphocytic leukemia
- CMS
Centers for Medicare & Medicaid Services
- COG
Children’s Oncology Group
- CRADA
Cooperative Research and Development Agreement
- CRI
Clinical Research Initiative (Association of American Cancer Institutes)
- CSDD
Center for the Study of Drug Development
- CT
computed tomography
- CTAC
Clinical Trials Advisory Committee
- CTEP
Cancer Therapy Evaluation Program
- CTMB
Clinical Trials Monitoring Branch
- CTROC
Clinical Trials and Translational Research Operations Committee
- CTSA
Clinical and Translational Science Awards
- CTSU
Cancer Trials Support Unit
- CTTI
Clinical Trials Transformation Initiative
- CTU
Clinical Trials Unit
- CTWG
Clinical Trials Working Group
- CYP2D6
cytochrome P-450 2D6
- DCE-MRI
dynamic contrast-enhanced magnetic resonance imaging
- DCPC
Division of Cancer Prevention and Control
- DCTD
Division of Cancer Treatment and Diagnosis
- DCTDC
Division of Cancer Treatment, Diagnosis, and Centers
- ECOG
Eastern Cooperative Oncology Group
- EGFR
epidermal growth factor receptor
- EMR
electronic medical record
- EORTC
European Organisation for Research and Treatment of Cancer
- ER
estrogen receptor
- ERISA
Employee Retirement Income Security Act of 1974
- 5-FU
fluorouracil
- 18F-FDG
fluorine-18 fluorodeoxyglucose
- FDA
Food and Drug Administration
- FDAAA
Food and Drug Administration Amendments Act of 2007
- FNIH
Foundation for the National Institutes of Health
- FOLFOX4
oxaliplatin, 5-fluorouracil, and leucovorin
- FTE
full-time equivalent
- GIST
gastrointestinal stromal tumors
- GOG
Gynecologic Oncology Group
- HER-2
human epidermal growth factor receptor 2
- HHS
U.S. Department of Health and Human Services
- HIPAA
Health Insurance Portability and Accountability Act
- ICF
informed-consent form
- IDB
Investigational Drug Branch
- IDE
investigational device exemption
- IND
investigational new drug
- IOM
Institute of Medicine
- IP
intellectual property
- IRB
institutional review board
- I-SPY TRIAL
Investigation of Serial studies to Predict Your Therapeutic Response with Imaging And moLecular analysis
- KRAS
Kirsten ras
- LOI
letter of intent
- MAMS
multiarm, multistage (trial design)
- MARVEL
Marker Validation for Erlotinib in Lung cancer
- MINDACT
Microarray in Node-negative Disease may Avoid ChemoTherapy
- MMRC
Multiple Myeloma Research Consortium
- MRC
Medical Research Council
- MRD
minimal residual disease
- MRI
magnetic resonance imaging
- NBL
neuroblastoma
- NCAB
National Cancer Advisory Board
- NCCF
National Children’s Cancer Foundation
- NCCN
National Comprehensive Cancer Network
- NCCTG
North Central Cancer Treatment Group
- NCD
National Coverage Decision
- NCI
National Cancer Institute
- NIH
National Institutes of Health
- NNCO
National Nanotechnology Coordination Office
- NSABP
National Surgical Adjuvant Breast and Bowel Project
- NSCLC
non-small-cell lung cancer
- NSET
Nanoscale Science, Engineering, and Technology Subcommittee
- OCR
Office for Civil Rights (U.S. Department of Health and Human Services)
- OEWG
Operational Efficiency Working Group
- OHRP
Office for Human Research Protections (U.S. Department of Health and Human Services)
- pCR
pathologic complete response
- PERCIST
PET Response Criteria in Solid Tumors
- PET
positron emission tomography
- Ph+
Philadelphia chromosome positive
- POG
Pediatric Oncology Group
- QIBA
Quantitative Imaging Biomarkers Alliance
- QOPI
Quality Oncology Practice Initiative
- RECIST
Response Evaluation Criteria in Solid Tumors
- RTOG
Radiation Therapy Oncology Group
- SACHRP
Secretary’s Advisory Committee on Human Research Protections
- SPECT
single-photon emission computed tomography
- SPORE
Specialized Programs of Research Excellence
- STAMPEDE
Systemic Therapy in Advancing or Metastatic Prostate Cancer: Evaluation of Drug Efficacy
- STPI
Science and Technology Policy Institute
- SWOG
Southwest Oncology Group
- TAILORx
Trial Assigning IndividuaLized Options for Treatment
- TRWG
Translational Research Working Group
- Tufts CSDD
Tufts Center for the Study of Drug Development
- US
ultrasound
- VA
U.S. Department of Veterans Affairs
- VEGF
vascular endothelial growth factor
- Acronyms - A National Cancer Clinical Trials System for the 21st CenturyAcronyms - A National Cancer Clinical Trials System for the 21st Century
Your browsing activity is empty.
Activity recording is turned off.
See more...